Results 51 to 60 of about 193,098 (314)

FoxO1 signaling in B cell malignancies and its therapeutic targeting

open access: yesFEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac   +3 more
wiley   +1 more source

Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment

open access: yesCancer Communications, Volume 42, Issue 12, Page 1387-1402, December 2022., 2022
Abstract Background Patients with refractory or relapsed acute myeloid leukemia (AML) have poor survival, necessitating the exploration of optimized therapeutic strategy. Here, we aimed to investigate clinical outcomes and health‐related quality of life (HR‐QoL) after total therapy, which included allogeneic hematopoietic stem cell transplantation ...
Chen‐hua Yan   +13 more
wiley   +1 more source

Dendritic Cells Are Critical for the Activation and Expansion of Vδ2+ T Cells After Allogeneic Hematopoietic Transplantation

open access: yesFrontiers in Immunology, 2018
γδ T cells perform antitumor and antiviral effector functions and are involved in both innate and adaptive immunity. Vδ2+ T cells represent the predominant γδ T subset in the peripheral blood of healthy subjects. Vδ2+ T cells can be selectively activated
Xiaoyu Wang   +8 more
doaj   +1 more source

Dynamics of a Mathematical Hematopoietic Stem-Cell Population Model [PDF]

open access: yesJournal on Applied Dynamical Systems, 18 (2019), 808-852, 2017
We explore the bifurcations and dynamics of a scalar differential equation with a single constant delay which models the population of human hematopoietic stem cells in the bone marrow. One parameter continuation reveals that with a delay of just a few days, stable periodic dynamics can be generated of all periods from about one week up to one decade ...
arxiv   +1 more source

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
Adaptive ERK reactivation hinders FLT3 tyrosine kinase inhibitor (TKI) treatment in FLT3/ITD acute myeloid leukemia. Here, we report that FLT3 TKI treatment rapidly induces AXL expression and upregulation that is temporally associated with the adaptive ERK reactivation.
Tessa S. Seale   +9 more
wiley   +1 more source

J‐SUPPORT research policy for oral mucositis associated with cancer treatment

open access: yesCancer Medicine, Volume 11, Issue 24, Page 4816-4829, December 2022., 2022
Abstract Background Oral mucositis is one of the main areas of research in supportive and palliative care of cancer patients. However, the methodology of prospective clinical trials on oral mucositis has not been established, despite its uniqueness.
Tomoya Yokota   +7 more
wiley   +1 more source

The Neuropsychiatry of Hematopoietic Stem Cell Transplantation [PDF]

open access: yesThe European Journal of Psychiatry, 2006
BACKGROUND AND OBJECTIVES: Regimens incorporating hematopoietic stem cell transplantation (HSCT) have become widely utilized in disease treatments, particularly for cancer. These complex treatment programs also expose patients to central nervous system (CNS) toxicities from chemotherapy, irradiation, infection, metabolic effects and immunosuppression ...
Levy, Mitchell R., Fann, Jesse R.
openaire   +3 more sources

Classification of acute myeloid leukemia based on multi‐omics and prognosis prediction value

open access: yesMolecular Oncology, EarlyView.
The Unsupervised AML Multi‐Omics Classification System (UAMOCS) integrates genomic, methylation, and transcriptomic data to categorize AML patients into three subtypes (UAMOCS1‐3). This classification reveals clinical relevance, highlighting immune and chromosomal characteristics, prognosis, and therapeutic vulnerabilities.
Yang Song   +13 more
wiley   +1 more source

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

open access: yesCancer Medicine, Volume 11, Issue 24, Page 4889-4899, December 2022., 2022
This analysis assessed safety and efficacy of lisocabtagene maraleucel (liso‐cel), an autologous CD‐19‐directed CAR T‐cell product, in Japanese patients with R/R aggressive LBCL in Cohort 3 of TRANSCEND WORLD (NCT03484702). Liso‐cel demonstrated meaningful efficacy and a manageable safety profile in Japanese patients with R/R LBCL.
Shinichi Makita   +11 more
wiley   +1 more source

Mesenchymal stem cells: A novel treatment option for primary sclerosing cholangitis

open access: yesCell Biology International, Volume 47, Issue 2, Page 467-479, February 2023., 2023
Abstract Primary sclerosing cholangitis (PSC) is a progressive liver disease for which there is no effective therapy. Hepatocytes and cholangiocytes from a PSC patient were cocultured with mesenchymal stem cells (MSCs) to assess in vitro change. A single patient with progressive PSC was treated with 150 million MSCs via direct injection into the common
Amy L. Lightner   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy